{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T04:26:41Z","timestamp":1760502401444,"version":"3.40.5"},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"20","license":[{"start":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:00:00Z","timestamp":1684454400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,5,19]]},"abstract":"<jats:sec>\n            <jats:title>Background and purpose:<\/jats:title>\n            <jats:p>Administration of pegylated granulocyte-colony-stimulating factor (peg-GCSF) 24 to 72 hours after chemotherapy is usually recommended. Next-day administration (after 24 hours) resulted in fewer duration of grade (Gr) 4 chemotherapy-induced neutropenia (CIN) and decreased severity of CIN than same-day (within 4 hours). However, patients sometimes receive same-day Peg-GCSF for the sake of convenience. In addition, a few prior studies showed that the same-day method is comparable or superior to the next-day method in preventing CIN, especially in chemotherapy regimens that include day 1 myelosuppressive agents. Thus, we aim to verify the hypothesis that same-day administration of pegteograstim, a new formulation of peg-GCSF, is non-inferior to next-day administration in terms of Gr4 CIN duration.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This study is a randomized, multicenter, open-label, investigator-initiated phase 3 study. Patients with adjuvant\/neoadjuvant or first-line palliative chemotherapy comprising intensively myelosuppressive agents on day 1 (mFOLFIRINOX, ECb, EP, FOLFIRI, and FOLFOX) are enrolled. The patients are assigned to the same-day arm or the next-day arm in a 1:1 ratio. The randomizations are stratified according to number of patient CIN risk factors (1 vs \u22652), chemotherapy setting (perioperative vs palliative), and interval (2-week vs 3-week). In the same-day arm, pegteograstim 6\u2009mg is subcutaneously injected within 4 hours after completion of chemotherapy. In the next-day arm, pegetograstim is injected at 24 to 36 hours post-chemotherapy. A complete blood count test is performed daily from day 5 to 9 during the cycle 1. The primary endpoint is duration of Gr4 CIN (cycle 1), and secondary endpoints include incidence of Gr 3 to 4 CIN (cycle 1), severity of CIN (cycle 1), time to recovery absolute neutrophil count 1000\/\u03bcL (cycle 1), incidence of febrile neutropenia, incidence of CIN-related dose delay, and dose intensity. In order to verify non-inferiority of 0.6 days, we estimated a significance level of 5%, power of 80%, and drop-out rate of 15%. This results in the need for a total of 160 patients, 80 in each group.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033638","type":"journal-article","created":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T23:02:23Z","timestamp":1684450943000},"page":"e33638","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Comparison of prophylactic effects for chemotherapy induced neutropenia between same-day versus next-day administration of pegteograstim (Neurapeg\u00ae) in patients treated with chemotherapy regimen composed of day 1 intensive myleosuppressive agent: A randomized phase III clinical trial"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7404-1257","authenticated-orcid":false,"given":"Kwonoh","family":"Park","sequence":"first","affiliation":[{"name":"Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea"},{"name":"Department of Internal Medicine, Hanyang University Seoul Hospital, Hanyang University College of Medicine, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Kyung","family":"Jeon","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Hoon","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Younak","family":"Choi","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jae-Joon","family":"Kim","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang-Bo","family":"Oh","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Yeon","family":"Oh","sequence":"additional","affiliation":[{"name":"Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jeong","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Neurology, Uijeongbu St. Mary\u2019s Hospital, Catholic University of Korea, Seoul, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Jae","family":"Huh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Dong-A University College of Medicine, Busan, Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhwan","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, South Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Hoon","family":"Shin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kosin University Gospel Hospital, Kosin University College of Medicine, Busan, Korea."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"12","DOI":"10.6004\/jnccn.2020.0002","article-title":"NCCN guidelines insights: hematopoietic growth factors, version 1.2020.","volume":"18","author":"Becker","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1634\/theoncologist.2016-0011","article-title":"A comparison of proposed biosimilar LA-EP2006 and reference pegfilgrastim for the prevention of neutropenia in patients with early-stage breast cancer receiving myelosuppressive adjuvant or neoadjuvant chemotherapy: pegfilgrastim randomized oncology (supportive care) trial to evaluate comparative treatment (PROTECT-2), a phase III, randomized, double-blind trial.","volume":"21","author":"Blackwell","year":"2016","journal-title":"Oncologist"},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1200\/JOP.091094","article-title":"Pegfilgrastim on the same day versus next day of chemotherapy in patients with breast cancer, non-small-cell lung cancer, ovarian cancer, and non-Hodgkin\u2019s lymphoma: results of four multicenter, double-blind, randomized phase II studies.","volume":"6","author":"Burris","year":"2010","journal-title":"J Oncol Pract"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/cncr.21847","article-title":"Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients.","volume":"106","author":"Kuderer","year":"2006","journal-title":"Cancer"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/annonc\/mdg019","article-title":"A randomized double-blind multicenter phase III study of fixed-dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy.","volume":"14","author":"Green","year":"2003","journal-title":"Ann Oncol"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/03007995.2018.1495621","article-title":"Risk of chemotherapy-induced febrile neutropenia with same-day versus next-day pegfilgrastim prophylaxis among patients aged \u226565 years: a retrospective evaluation using Medicare claims.","volume":"34","author":"Weycker","year":"2018","journal-title":"Curr Med Res Opin"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1007\/s00520-015-3036-7","article-title":"Risk of chemotherapy-induced febrile neutropenia in cancer patients receiving pegfilgrastim prophylaxis: does timing of administration matter?","volume":"24","author":"Weycker","year":"2016","journal-title":"Support Care Cancer"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1007\/s00520-014-2270-8","article-title":"Efficacy and safety of early G-CSF administration in patients with head and neck cancer treated by docetaxel-cisplatin and 5-fluorouracil (DCF protocol): a retrospective study.","volume":"22","author":"Linot","year":"2014","journal-title":"Support Care Cancer"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.1007\/s00520-015-2963-7","article-title":"A randomized, multicenter, phase II\/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteograstim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09.","volume":"24","author":"Lee","year":"2016","journal-title":"Support Care Cancer"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update.","volume":"33","author":"Smith","year":"2015","journal-title":"J Clin Oncol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033638","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T02:04:13Z","timestamp":1746324253000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,19]]},"references-count":10,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033638","relation":{},"ISSN":["0025-7974"],"issn-type":[{"type":"print","value":"0025-7974"}],"subject":[],"published":{"date-parts":[[2023,5,19]]}}}